Clinical trial

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid…

NCT00107354 · Fred Hutchinson Cancer Center, Other · Completed

Key facts

NCT number NCT00107354
Title Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Official title Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor Fred Hutchinson Cancer Center, Other
Status Completed
Phase Phase 1
Study type Interventional
Conditions Leukemia, Myelodysplastic Syndromes
Intervention type Biological, Drug, Procedure
Interventions aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes, cytarabine, etoposide, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Start date Dec 1, 1998
Primary completion Aug 1, 2009
First posted Apr 6, 2005
Last update posted Sep 20, 2010
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies